Search

Your search keyword '"Penault-Llorca, F."' showing total 1,084 results

Search Constraints

Start Over You searched for: Author "Penault-Llorca, F." Remove constraint Author: "Penault-Llorca, F."
1,084 results on '"Penault-Llorca, F."'

Search Results

1. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial

2. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

3. Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe

6. European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

8. Delayed care for patients with newly diagnosed cancer due to COVID-19 and estimated impact on cancer mortality in France

10. Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future

11. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

12. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network

13. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

15. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

22. 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3)

27. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

29. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact

32. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

34. Potential histological discordance revealed by second review in the national rare gynecological cancer network (TMRG)

41. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

42. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

45. 159P SiMosein, a real-life prospective evaluation of EndoPredict use in early ER-positive, HER2-negative breast cancers

48. Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†

49. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

Catalog

Books, media, physical & digital resources